Imiquimod
Molluscum Contagiosum, Condylomata Acuminata, Carcinoma, Basal Cell + 3 more
Treatment
8 FDA approvals
0 Active Studies for Imiquimod
Treatment for
Molluscum Contagiosum
What is Imiquimod
Imiquimod
The Generic name of this drug
Treatment Summary
Imiquimod is a medicine used to treat skin conditions caused by viruses, such as warts on the genital and anal areas. It does not kill the virus that causes warts, but it can help stop new warts from appearing. Imiquimod can also be used to treat actinic keratoses, a skin condition that affects the face and scalp, as well as some types of skin cancer called superficial basal cell carcinoma.
Aldara
is the brand name
Imiquimod Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Aldara
Imiquimod
1997
27
Approved as Treatment by the FDA
Imiquimod, also known as Aldara, is approved by the FDA for 8 uses like Face and Actinic Keratoses of the scalp .
Face
Actinic Keratoses of the scalp
Actinic Keratoses of the face
Superficial Basal Cell Carcinoma
Condylomata Acuminata
Scalp structure
Carcinoma, Basal Cell
Condylomata Acuminata
Effectiveness
How Imiquimod Affects Patients
Imiquimod is a medication used to help control the growth of warts on the skin, usually in the genital and anal areas. It does not cure warts or attack the virus that causes them, but it does reduce the amount of warts appearing. Imiquimod is not recommended for use inside the vagina, penis, or rectum. It is also used to treat actinic keratoses and certain types of skin cancer (superficial basal cell carcinoma) on areas such as the face and lower legs, where surgery or other treatments may not be feasible.
How Imiquimod works in the body
Imiquimod works by activating the immune system to respond to the treated area. It does not directly fight viruses, but it does encourage the body to produce certain proteins that help fight off infection. In the case of treating basal cell carcinoma, imiquimod triggers the immune system to send in lymphocytes, dendritic cells, and macrophages to fight off the cancerous cells. It also stimulates apoptosis, which is the programmed death of unhealthy cells in the area.
When to interrupt dosage
The specified dosage of Imiquimod is contingent upon the diagnosed disorder, such as Communicable Diseases, Face and Superficial Basal Cell Carcinoma. The amount likewise fluctuates as per the technique of delivery (e.g. Cream - Topical or Topical) highlighted in the table beneath.
Condition
Dosage
Administration
Face
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Gel - Topical, Gel, Cutaneous, Cream - Cutaneous
Condylomata Acuminata
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Gel - Topical, Gel, Cutaneous, Cream - Cutaneous
Carcinoma, Basal Cell
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Gel - Topical, Gel, Cutaneous, Cream - Cutaneous
Communicable Diseases
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Gel - Topical, Gel, Cutaneous, Cream - Cutaneous
Molluscum Contagiosum
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Gel - Topical, Gel, Cutaneous, Cream - Cutaneous
Scalp structure
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Gel - Topical, Gel, Cutaneous, Cream - Cutaneous
Warnings
Imiquimod Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 6 known major drug interactions with Imiquimod.
Common Imiquimod Drug Interactions
Drug Name
Risk Level
Description
Allogeneic processed thymus tissue
Minor
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Imiquimod.
Inebilizumab
Minor
The risk or severity of infection can be increased when Imiquimod is combined with Inebilizumab.
Vibrio cholerae CVD 103-HgR strain live antigen
Minor
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Imiquimod.
Haloperidol
Moderate
The serum concentration of Haloperidol can be increased when it is combined with Imiquimod.
Magnesium
Moderate
The serum concentration of Magnesium can be decreased when it is combined with Imiquimod.
Imiquimod Toxicity & Overdose Risk
Overdosing on ibuprofen can lead to flu-like symptoms, including fever, fatigue, headache, nausea, diarrhea, and muscle pain.
Imiquimod Novel Uses: Which Conditions Have a Clinical Trial Featuring Imiquimod?
Currently, 9 active clinical trials are underway to investigate the efficacy of Imiquimod in treating Molluscum Contagiosum, Facial conditions and Condylomata Acuminata.
Condition
Clinical Trials
Trial Phases
Condylomata Acuminata
0 Actively Recruiting
Carcinoma, Basal Cell
0 Actively Recruiting
Scalp structure
0 Actively Recruiting
Molluscum Contagiosum
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Face
0 Actively Recruiting
Imiquimod Reviews: What are patients saying about Imiquimod?
5
Patient Review
9/25/2019
Imiquimod for Vulvar Intraepithelial Neoplasia
5
Patient Review
5/11/2021
Imiquimod for External Genital Warts
4.3
Patient Review
11/24/2020
Imiquimod for External Genital Warts
4
Patient Review
4/15/2021
Imiquimod for Superficial Basal Cell Carcinoma of the Skin
3.3
Patient Review
8/16/2022
Imiquimod for External Genital Warts
3
Patient Review
7/17/2022
Imiquimod for External Genital Warts
2.3
Patient Review
8/21/2021
Imiquimod for Roughened Red Patches of Skin due to Sun Exposure
2
Patient Review
9/3/2022
Imiquimod for Superficial Basal Cell Carcinoma of the Skin
2
Patient Review
2/3/2019
Imiquimod for Roughened Red Patches of Skin due to Sun Exposure
1.7
Patient Review
4/27/2019
Imiquimod for Roughened Red Patches of Skin due to Sun Exposure
1.3
Patient Review
2/27/2022
Imiquimod for External Genital Warts
1.3
Patient Review
3/22/2022
Imiquimod for External Genital Warts
Patient Q&A Section about imiquimod
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is imiquimod a steroid?
"Imiquimod has been shown to be a very effective therapy for superficial basal cell Carcinoma, squamous cell carcinoma, and actinic keratosis.
Imiquimod is a non-steroidal medication that increases the activity of the immune system. It is available under the trade names Aldara and Zyclara. It is primarily available as a cream. Imiquimod has been shown to be a very effective therapy for superficial basal cell Carcinoma, squamous cell carcinoma, and actinic keratosis."
Answered by AI
What is imiquimod used to treat?
"Imiquimod is a medication used to treat superficial basal cell carcinoma, a type of skin cancer. It works by activating the immune system to help the body fight viruses that cause warts. It is not known how imiquimod works for actinic keratosis or skin cancer."
Answered by AI
How long does it take for imiquimod to work?
"The majority of patients observed complete wart clearance after using 5% imiquimod cream. Of those who saw wart disappearance, 44% were clear by 8 weeks and 69% were clear by 12 weeks. Out of the total patients using the cream, 77% of women and 40% of men experienced complete wart clearance."
Answered by AI
How does imiquimod work on HPV?
"Imiquimod can kill viral infected cells and tumour cells by inducing programmed cell death. If more HPV infected KCs are made apoptotic when Langerhans cells are activated by imiquimod, more HPV related antigens will be taken up and processed by LCs, activating a more robust adaptive immune response."
Answered by AI